RNA based therapeutics has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, AIDS, Tuberculosis and certain cardiovascular conditions. Despite being in the clinical research phase, the RNA based therapeutics is been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. RNAi technology works by causing destruction of specific mRNA molecules; whereas, antisense technology works by synthesizing strand of RNA from known gene sequence. These newly synthesized RNA strands then itself binds to mRNA and make mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field. Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies. Quark Pharmaceuticals, Inc. (USA), Alnylam Pharmaceuticals, Inc. (USA), Dicerna Pharmaceuticals, Inc. (USA), Tekmira Pharmaceuticals Corp. (Canada), Benitec Biopharma Limited (Australia), Genzyme Corporation (USA), ISIS pharmaceuticals Inc (USA), Silence Therapeutics PLC (UK) and Cenix BioScience GmbH (Germany) are some of the key players in this market. ISIS pharmaceuticals, Inc. (USA) has focused its research activities on antisense technology and developed antisense therapeutics, namely Mipomersen and Fomivirsen. This therapeutics is commercially available in the market and marketed as Kynamro and Vitravene respectively. Quark, Alnylam and silence therapeutics are other major players of this market with strong research pipeline in RNA based therapeutics.
RNA based therapeutics market is segmented into technology, application, end-users and geography. Technology segment is further categorized as enabling technologies and enabled technologies. The segment of enabling technologies comprises of Microarrays, Labeling, Purification, Linear amplification, qRT-PCR and Inhibition; whereas, enabled technologies includes RNA interference technology (RNAi) and RNA antisense technology. Enabled technologies account for largest market share due to their potential use in therapeutics. The market for RNA based therapeutics is dominated by RNA interference technology as numerous companies have exhibited their interest to develop the RNA drugs using RNAi technology. RNA based therapeutics have wide applications covering variety of chronic conditions such as Cardiovascular, Kidney Diseases, Oncology, Infectious diseases, Metabolic disorders and Others. The pipeline research is concentrated towards oncology and infectious diseases due to their high prevalence and failure of existing treatment to effectively treat these conditions. The end user market is segmented into research, therapeutics and diagnostics. Currently, research and diagnostics segments are largely exploring the RNA technologies and therapies for the commercialization of RNA drugs.
Geographically, RNA based therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Potential regions of the respective geographies are strategically analyzed to provide country wise focus on RNA research activities. North America dominates the RNA based therapeutics followed by Europe and Asia-Pacific. The key market players belong to North America and are conducting extensive research to commercialize the therapeutics. Moreover, the growth in North America and Europe is primarily driven by substantial investment on research, advancement in RNA platform technologies, government support and availability of suitable infrastructure to develop the novel RNA based therapies. However, business dynamics in Asia-pacific is anticipated to offer tremendous opportunities to major players of this market as cost of clinical research is less in this region as compared to North America and Europe.
KEY BENEFITS
KEY MARKET SEGMENTS
RNA based therapeutics market is segmented into four major categories such as Technology, Application, End Users and Geography.
MARKET BY TECHNOLOGY
MARKET BY APPLICATION
MARKET BY END USERS
MARKET BY GEOGRAPHY
CHAPTER 1 INTRODUCTION
1.1 Report Description
1.2 Reason for doing the study
1.3 Key Benefits
1.4 Key Market Segments
1.5 Key Audiences
1.6 Research Methodology
1.6.1 Secondary Research
1.6.2 Primary Research
1.6.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2025
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Historical perspective and current market trends
3.3 SMaRT RNA Technology- A promising Tool To Target Disease Causing RNAs
3.4 Conventional Vs RNA-based therapeutics
3.5 Addressable Market Analysis
3.5.1 DNA based therapeutics
3.5.2 RNA based thearpeutics
3.6 Key Findings
3.6.1 Top Factors Impacting on RNA based therapeutics market
3.6.2 Top Investment Pockets of RNA based therapeutics market
3.6.3 Top winning strategies of RNA based therapeutics market
3.7 Government Regulations
3.7.1 USFDA Perspective
3.7.2 European Union Perspective
3.8 Porter five force model
3.8.1 Bargaining power of buyers (Low)
3.8.2 Bargaining power of suppliers(High)
3.8.3 Threat of new entrants (High)
3.8.4 Threat of substitute products (Moderate)
3.8.5 Intensity of competitive rivalry (Strong)
3.9 Value chain analysis
3.9.1 Primary activities
3.9.2 Support Activities
3.10 Pipeline Review
3.11 Patent Analysis
3.11.1 Patent analysis by geographies(2010-2014)
3.12 Clinical Trials For RNA Based Therapeutics
3.13 Market Dynamics
3.13.1 Drivers
3.13.1.1 Target specificty and selectivity of treatment
3.13.1.2 Strategic Alliances and Funding
3.13.1.3 More intense product focus against platform technology
3.13.1.4 Promising technologies driving the RNA based therapeutics
3.13.1.5 Adoption of virtual drug development models
3.13.2 Restraints
3.13.2.1 Hurdles in drug delivery
3.13.2.2 High cost of research and threat of failure
3.13.3 Opportunities
3.13.3.1 Early commercialization of pipeline therapeutics assists to gain competitive advantage
3.13.3.2 Multifactorial disease targeting
CHAPTER 4 GLOBAL RNA BASED THERAPEUTICS MARKET BY TECHNOLOGIES, 2013-2020, $MILLION
4.1 Enabling technologies
4.1.1 Microarrays
4.1.2 Labelling
4.1.3 Purification
4.1.4 Linear amplification
4.1.5 qRT-PCR
4.1.6 Inhibition
4.2 Enabled technologies
4.2.1 RNA Interference (RNAi) technologies
4.2.1.1 Market Dynamics
4.2.1.1.1 DRIVERS
4.2.1.1.2 RESTRAINTS
4.2.1.1.3 OPPORTUNITIES
4.2.1.2 Competitive scenario
4.2.1.3 Small interfering RNA (siRNA)
4.2.1.4 MicroRNA (miRNA)
4.2.1.5 Market size & forecast
4.2.2 RNA antisense technologies
4.2.2.1 Market Dynamics
4.2.2.1.1 DRIVERS
4.2.2.1.2 RESTRAINTS
4.2.2.1.3 OPPORTUNITIES
4.2.2.2 Competitive scenario
4.2.2.3 Market size & forecast
CHAPTER 5 GLOBAL RNA BASED THERAPEUTICS MARKET BY APPLICATIONS, 2013-2020, $MILLION
5.1 Cardiovascular
5.1.1 Global Cardiac Disease Incidences
5.1.1.1 Facts for cardiac diseases
5.1.2 Adoption Drivers
5.1.3 Market Size and Forecast
5.2 Kidney Diseases
5.2.1 Global Renal Disease Incidences
5.2.2 Adoption Drivers
5.2.3 Market Size and Forecast
5.3 Oncology
5.3.1 Global Cancer Incidences
5.3.2 Adoption Drivers
5.3.3 Market Size and Forecast
5.4 Infectious diseases
5.4.1 Global Infectious Disease Incidences
5.4.1.1 Tuberculosis
5.4.1.2 HIV and AIDS
5.4.2 Adoption Drivers
5.4.3 Market Size and Forecast
5.5 Metabolic disorders
5.5.1 Global Metabolic Disorders by Type
5.5.1.1 Obesity
5.5.1.2 Diabetes
5.5.2 Adoption Drivers
5.5.3 Market Size and Forecast
5.6 Others
CHAPTER 6 GLOBAL RNA BASED THERAPEUTICS MARKET BY END USERS, 2013-2020, $MILLION
6.1 Research
6.2 Therapeutics
6.3 Diagnosis
CHAPTER 7 GLOBAL RNA BASED THERAPEUTICS MARKET BY GEOGRAPHY, 2013-2020, $MILLION
7.1 North America
7.1.1 United States
7.1.1.1 Pipeline Review
7.1.1.2 Market Trends
7.1.1.3 Competitive scenario
7.1.1.4 Key growth factors and opportunities
7.1.2 Canada
7.1.2.1 Pipeline Review
7.1.2.2 Key market trends
7.1.2.3 Competitive scenario
7.1.2.4 Key growth factors and opportunities
7.2 Europe
7.2.1 Germany
7.2.1.1 Pipeline Review
7.2.1.2 Key market trends
7.2.1.3 Competitive scenario
7.2.1.4 Key growth factors and opportunities
7.2.2 United Kingdom
7.2.2.1 Pipeline Review
7.2.2.2 Key market trends
7.2.2.3 Competitive scenario
7.2.2.4 Key growth factors and opportunities
7.2.3 France
7.2.4 Others
7.3 Asia-Pacific
7.3.1 Pipeline Review
7.3.2 Key market trends
7.3.3 Competitive scenario
7.3.4 Key growth factors and opportunities
7.3.5 Market size and forecast
7.4 LAMEA
7.4.1 Pipeline Review
7.4.2 Key market trends
7.4.3 Competitive scenario
7.4.4 Key growth factors and opportunities
7.4.5 Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1 Quark Pharmaceuticals, Inc. (USA)
8.1.1 Company overview
8.1.2 Company snapshots
8.1.3 Strategic moves and developments
8.1.3.1 Principal Strategy
8.1.3.2 Secondary Strategy
8.1.4 SWOT Analysis
8.2 Alnylam Pharmaceuticals, Inc. (USA)
8.2.1 Company overview
8.2.2 Company snapshots
8.2.3 Business Performance
8.2.4 Strategic moves and developments
8.2.4.1 Principal Strategy
8.2.4.2 Secondary Strategy
8.2.5 SWOT Analysis
8.3 Dicerna Pharmaceuticals, Inc. (USA)
8.3.1 Company overview
8.3.2 Company snapshots
8.3.3 Business Performance
8.3.4 Strategic moves and developments
8.3.5 SWOT Analysis
8.4 Tekmira Pharmaceuticals Corp. (Canada)
8.4.1 Company overview
8.4.2 Company snapshots
8.4.3 Business Performance
8.4.4 Strategic moves and developments
8.4.4.1 Principal Strategy
8.4.4.2 Secondary Strategy
8.4.5 SWOT Analysis
8.5 Benitec Biopharma Limited (Australia)
8.5.1 Company overview
8.5.2 Company snapshots
8.5.3 Strategic moves and developments
8.5.3.1 Principal Strategy
8.5.3.2 Secondary Strategy
8.5.4 SWOT Analysis
8.6 Cenix BioScience GmbH (Germany)
8.6.1 Company overview
8.6.2 Company snapshots
8.6.3 Strategic moves and developments
8.6.3.1 Principal Strategy
8.6.3.2 Secondary Strategy
8.6.4 SWOT Analysis
8.7 Genzyme Corporation (USA) (A Sanofi Company)
8.7.1 Company overview
8.7.2 Company snapshots
8.7.3 Business performance
8.7.4 SWOT Analysis
8.8 Silence Therapeutics PLC (UK)
8.8.1 Company overview
8.8.2 Company snapshots
8.8.3 Business performance
8.8.4 Strategic moves and developments
8.8.4.1 Principal Strategy
8.8.4.2 Secondary Strategy
8.8.5 SWOT Analysis
8.9 Sirnaomics, Inc. (USA)
8.9.1 Company overview
8.9.2 Company snapshots
8.9.3 Strategic moves and developments
8.9.3.1 Principal Strategy
8.9.3.2 Secondary Strategy
8.9.4 SWOT Analysis
List of Figures
FIG. 1 TOP FACTORS IMPACTING RNA BASED THERAPEUTICS MARKET (2014-2020)
FIG. 2 TOP WINING STRATEGIES FOR RNA BASED THERAPEUTICS MARKET (2011-2013)
FIG. 3 TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENT
FIG. 4 PORTER’S FIVE FORCE ANALYSIS OF RNA BASED THERAPEUTICS MARKET
FIG. 5 VALUE CHAIN ANALYSIS OF RNA BASED THERAPEUTICS MARKET
FIG. 6 PIPELINE REVIEW OF RNA BASED THERAPEUTICS
FIG. 7 PATENT ANALYSIS BY GEOGRAPHIES (2011-2014)
FIG. 8 PATENT ANALYSIS BY GEOGRAPHIES BASED ON TECHNOLOGY(2011-2014)
FIG. 9 CLINICAL PHASE STATUS: RNAI THERAPIES
FIG. 10 CLINICAL PHASE STATUS: ANTISENSE THERAPIES
FIG. 11 GLOBAL RENAL DISEASES INCIDENCES: GLOBAL VIEW OF DIALYSIS PATIENTS (2012)
FIG. 12 GLOBAL CANCER INCIDENCES BASED ON COMMON CANCER TYPES (2012)
FIG. 13 NUMBER OF NEW INFECTIOUS DISEASE CASES IN UNITED STATES (2011)
FIG. 14 WHO ESTIMATES OF TUBERCULOSIS INCIDENCE BY WHO REGION (THOUSANDS) (2012)
FIG. 15 PREVALENCE OF OBESITY (2013); AGE 20 YEARS AND OLDER (%)
FIG. 16 TOP TEN COUNTRIES FOR NUMBER OF PEOPLE WITH DIABETES AGED BETWEEN 20-79 YEARS (2013, MILLION)
FIG. 17 SWOT ANALYSIS OF QUARK PHARMACEUTICALS, INC.
FIG. 18 ALNYLAM’S NET REVENUE FROM RESEARCH COLLABORATORS (2012)
FIG. 19 SWOT ANALYSIS OF ALNYLAM PHARMACEUTICALS, INC.
FIG. 20 OPERATING EXPENSES OF DICERNA PHARMACEUTICALS INC. (2013)
FIG. 21 SWOT ANALYSIS OF DICERNA PHARMACEUTICALS, INC.
FIG. 22 TEKMIRA’S NET REVENUE FROM COLLABORATIONS AND CONTRACTS (2013)
FIG. 23 SWOT ANALYSIS OF TEKMIRA PHARMACEUTICALS CORPORATION
FIG. 24 SWOT ANALYSIS OF BENITEC BIOPHARMA LIMITED
FIG. 25 SWOT ANALYSIS OF CENIX BIOSCIENCE GMBH
FIG. 26 BUSINESS PERFORMANCE SANOFI S.A. BY GEOGRAPHIES (2013)
FIG. 27 BUSINESS PERFORMANCE OF SANOFI S.A. BY BUSINESS SEGMENTS (2013)
FIG. 28 SWOT ANALYSIS OF SANOFI S.A.
FIG. 29 BUSINESS PERFORMANCE SANOFI S.A. BY GEOGRAPHIES (2013)
FIG. 30 SWOT ANALYSIS OF SILENCE THERAPEUTICS PLC
FIG. 31 SWOT ANALYSIS OF SIRNAOMICS, INC.
List of Tables
TABLE 1 CONVENTIONAL VS RNA-BASED THERAPEUTICS
TABLE 2 TOP INVESTMENT POCKETS OF RNA BASED THERAPEUTICS MARKET (2013)
TABLE 3 LIST OF EMA DOCUMENTS AND GUIDELINES
TABLE 4 PATENT ANALYSIS BY GEOGRAPHIES(2010-2014)
TABLE 5 CLINICAL TRIALS FOR RNA BASED THERAPEUTICS
TABLE 6 PIPELINE RNA THERAPEUTICS AND THEIR SPECIFIC TARGET
TABLE 7 LIST OF STRATEGIC ALLIANCES FOR THE DEVELOPMENT OF RNA-BASED THERAPEUTICS
TABLE 8 LIST OF COMPANIES USING DIFFERENT RNA TECHNOLOGIES
TABLE 9 GLOBAL RNA BASED THERAPEUTICS MARKET BY TECHNOLOGIES, 2013 – 2020 ($MILLION)
TABLE 10 PRICES OF RNA PURIFICATION KITS
TABLE 11 PRICES OF LINEAR AMPLIFICATION KIT
TABLE 12 PIPELINE RESEARCH STATUS: RNAI THERAPIES
TABLE 13 PRICE CHART FOR SIRNA
TABLE 14 COMPANIES AND THEIR MIRNA TECHNOLOGIES
TABLE 15 PRICE CHART FOR MIRNA
TABLE 16 GLOBAL RNA INTERFERENCE (RNAI) TECHNOLOGY MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 17 GLOBAL RNA ANTISENSE TECHNOLOGY MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 18 GLOBAL RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 19 GLOBAL RNA BASED THERAPEUTICS CARDIOVASCULAR APPLICATIONS MARKET, BY GEOGRA PHY, 2013 – 2020 ($MILLION)
TABLE 20 GLOBAL RNA BASED THERAPEUTICS KIDNEY DISEASES APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 21 GLOBAL CANCER INCIDENCE, MORTALITY AND PREVALENCE (2012)
TABLE 22 GLOBAL RNA BASED THERAPEUTICS ONCOLOGY APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 23 REGIONAL STATISTICS FOR HIV AND AIDS (2011)
TABLE 24 GLOBAL RNA BASED THERAPEUTICS INFECTIOUS DISEASES APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 25 GLOBAL RNA BASED THERAPEUTICS METABOLIC DISORDERS APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 26 GLOBAL RNA BASED THERAPEUTICS OTHER APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 27 GLOBAL RNA BASED THERAPEUTICS MARKET REVENUE, BY END USERS, 2013 – 2020 ($MILLION)
TABLE 28 RESEARCH COLLABORATIONS FOR RNA-BASED THERAPEUTICS
TABLE 29 REGION/COUNTRIES AND THEIR RESPECTIVE FUNDING AGENCIES
TABLE 30 GLOBAL RESEARCH MARKET REVENUE, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 31 LIST OF RNA BASED THERAPEUTICS : APPROVED AND PHASE IIB & PHASE III CLINICAL TRIALS
TABLE 32 GLOBAL THERAPEUTICS MARKET REVENUE, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 33 RNA DIAGNOSTIC COMPANIES AND THEIR CORE PRODUCTS
TABLE 34 GLOBAL DIAGNOSIS MARKET REVENUE, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 35 GLOBAL RNA BASED THERAPEUTICS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 36 NORTH AMERICA RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 37 UNITED STATES: PIPELINE REVIEW
TABLE 38 EUROPE RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 39 ASIA- PACIFIC RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 40 LAMEA RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 41 QUARK PHARMACEUTICALS, INC.
TABLE 42 ALNYLAM PHARMACEUTICALS SNAPSHOT
TABLE 43 DICERNA PHARMACEUTICALS, INC.SNAP SHOT
TABLE 44 TEKMIRA PHARMACEUTICALS CORPORATION SNAP SHOT
TABLE 45 BENITEC BIOPHARMA SNAPSHOT
TABLE 46 CENIX BIOSCIENCE SNAPSHOT
TABLE 47 GENZYME CORPORATION SNAPSHOT
TABLE 48 SILENCE THERAPEUTICS PLC SNAPSHOT
TABLE 49 SIRNAOMICS, INC SNAPSHOT
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
